123 related articles for article (PubMed ID: 27279063)
1. Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate and indapamide as active substances using experimental design.
Szabó ZI; Székely-Szentmiklósi B; Deák B; Székely-Szentmiklósi I; Kovács B; Zöldi K; Sipos E
Acta Pharm; 2016 Jun; 66(2):191-206. PubMed ID: 27279063
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of a new formulation of enalapril maleate tablet.
Bibi R; Naqvi BS; Shoaib MH; Rahim N
Pak J Pharm Sci; 2011 Apr; 24(2):211-5. PubMed ID: 21454172
[TBL] [Abstract][Full Text] [Related]
3. Continuous manufacturing and analytical characterization of fixed-dose, multilayer orodispersible films.
Thabet Y; Lunter D; Breitkreutz J
Eur J Pharm Sci; 2018 May; 117():236-244. PubMed ID: 29499348
[TBL] [Abstract][Full Text] [Related]
4. Use of microcalorimetry in determination of stability of enalapril maleate and enalapril maleate tablet formulations.
Simoncic Z; Zupancic P; Roskar R; Gartner A; Kogej K; Kmetec V
Int J Pharm; 2007 Sep; 342(1-2):145-51. PubMed ID: 17597314
[TBL] [Abstract][Full Text] [Related]
5. Proposal of a new degradation mechanism of enalapril maleate and improvement of enalapril maleate stability in tablet formulation with different stabilizers.
Chen J; Zhang LH; Xu RJ; Bu NJ; Zhang L
Pharmazie; 2014 Apr; 69(4):277-80. PubMed ID: 24791591
[TBL] [Abstract][Full Text] [Related]
6. Influence of different types of commercially available microcrystalline cellulose on degradation of perindopril erbumine and enalapril maleate in binary mixtures.
Vehovec T; Gartner A; Planinšek O; Obreza A
Acta Pharm; 2012 Dec; 62(4):515-28. PubMed ID: 23333887
[TBL] [Abstract][Full Text] [Related]
7. New Orodispersible Mini Tablets of Enalapril Maleate by Direct Compression for Pediatric Patients.
Ortega CA; Favier LS; Cianchino VA; Cifuente DA
Curr Drug Deliv; 2020; 17(6):505-510. PubMed ID: 32384031
[TBL] [Abstract][Full Text] [Related]
8. Role of continuous moisture profile monitoring by inline NIR spectroscopy during fluid bed granulation of an Enalapril formulation.
Hartung A; Knoell M; Schmidt U; Langguth P
Drug Dev Ind Pharm; 2011 Mar; 37(3):274-80. PubMed ID: 20815795
[TBL] [Abstract][Full Text] [Related]
9. Enalapril maleate orally disintegrating tablets: tableting and in vivo evaluation in hypertensive rats.
Tawfeek HM; Faisal W; Soliman GM
Pharm Dev Technol; 2018 Jun; 23(5):496-503. PubMed ID: 28489472
[TBL] [Abstract][Full Text] [Related]
10. Effect of disintegrants on the properties of multiparticulate tablets comprising starch pellets and excipient granules.
Mehta S; De Beer T; Remon JP; Vervaet C
Int J Pharm; 2012 Jan; 422(1-2):310-7. PubMed ID: 22101283
[TBL] [Abstract][Full Text] [Related]
11. Enalapril maleate form II: stabilization in a tablet formulation.
Eyjolfsson R
Pharmazie; 2003 May; 58(5):357. PubMed ID: 12779058
[No Abstract] [Full Text] [Related]
12. Formulation and in-vitro evaluation of floating bilayer tablet of lisinopril maleate and metoprolol tartrate.
Ijaz H; Qureshi J; Danish Z; Zaman M; Abdel-Daim M; Hanif M; Waheed I; Mohammad IS
Pak J Pharm Sci; 2015 Nov; 28(6):2019-25. PubMed ID: 26639495
[TBL] [Abstract][Full Text] [Related]
13. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations.
Al-Omari MM; Abdelah MK; Badwan AA; Jaber AM
J Pharm Biomed Anal; 2001 Jul; 25(5-6):893-902. PubMed ID: 11377072
[TBL] [Abstract][Full Text] [Related]
14. Effect of binders on anti hypertensive drugs.
Agrawal YK; Majumdar F
Boll Chim Farm; 1999 Nov; 138(10):531-43. PubMed ID: 10765470
[TBL] [Abstract][Full Text] [Related]
15. Stability of extemporaneous enalapril maleate suspensions for pediatric use prepared from commercially available tablets.
Sosnowska K; Winnicka K; Czajkowska-Kośnik A
Acta Pol Pharm; 2009; 66(3):321-6. PubMed ID: 19645333
[TBL] [Abstract][Full Text] [Related]
16. A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes.
Kushner J; Langdon BA; Hicks I; Song D; Li F; Kathiria L; Kane A; Ranade G; Agarwal K
J Pharm Sci; 2014 Feb; 103(2):527-38. PubMed ID: 24375069
[TBL] [Abstract][Full Text] [Related]
17. Enalapril maleate polymorphs: instability of form II in a tablet formulation.
Eyjolfsson R
Pharmazie; 2002 May; 57(5):347-8. PubMed ID: 12061263
[No Abstract] [Full Text] [Related]
18. Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications.
Lima DM; dos Santos LD; Lima EM
J Pharm Biomed Anal; 2008 Aug; 47(4-5):934-7. PubMed ID: 18472382
[TBL] [Abstract][Full Text] [Related]
19. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets.
Pabari RM; Ramtoola Z
Int J Pharm; 2012 Jul; 430(1-2):18-25. PubMed ID: 22465631
[TBL] [Abstract][Full Text] [Related]
20. The role of intra- and extragranular microcrystalline cellulose in tablet dissolution.
Li JZ; Rekhi GS; Augsburger LL; Shangraw RF
Pharm Dev Technol; 1996 Dec; 1(4):343-55. PubMed ID: 9552318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
